News

PAVmed, Lucid post encouraging results from EsoGuard study
Study shows Lucid's EsoGuard test detects esophageal precancer in at-risk patients without symptoms. Read more here.
Lucid Diagnostics Reports Positive Data for EsoGuard in Study of Asymptomatic Patients
Lucid Diagnostics shared new data from a National Cancer Institute (NCI)-sponsored study that supports the broader utility of its EsoGuard(R) Esophageal DNA Test. The study, condu ...
Lucid Diagnostics’ EsoGuard DNA Test shows cancer detection efficacy in study
Lucid Diagnostics (LUCD) announced positive data from a National Cancer Institute-sponsored study demonstrating that its EsoGuard Esophageal ...
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced ...